Bo Fu

Bo Fu

Sanofi US - New Jersey / United States
Medical and Health Sciences / Biostatistics
AD Scientific Index ID: 4392085
-
person_outline Bo Fu's MOST POPULAR ARTICLES
1-) Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infectionS Zeuzem, GR Foster, S Wang, A Asatryan, E Gane, JJ Feld, T Asselah, ...New England Journal of Medicine 378 (4), 354-369, 20184012018
2-) Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeksJJ Feld, C Moreno, R Trinh, E Tam, S Bourgeois, Y Horsmans, ...Journal of hepatology 64 (2), 301-307, 20162372016
3-) Engagement in social activities and progression from mild to severe cognitive impairment: the MYHAT studyTF Hughes, JD Flatt, B Fu, CCH Chang, M GanguliInternational psychogeriatrics 25 (4), 587-595, 20131842013
4-) Mild cognitive impairment: incidence and vascular risk factors in a population-based cohortM Ganguli, B Fu, BE Snitz, TF Hughes, CCH ChangNeurology 80 (23), 2112-2120, 20131852013
5-) Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infectionH Toyoda, K Chayama, F Suzuki, K Sato, T Atarashi, T Watanabe, ...Hepatology 67 (2), 505-513, 20181342018